This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.
In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.
In your application messsage, please share your background and what you can contribute to the group.
Company Overview and News
HERSHEY, Pa., July 17, 2018 (GLOBE NEWSWIRE) -- The Hershey Company (NYSE:HSY) was recognized for the sixth time as one of America’s 50 most community-minded companies in The Civic 50, an annual recognition from Points of Light for companies that most effectively use their resources to help improve the communities in which they do business.
Cocoa is a member of the soft commodities sector that trades on the Intercontinental Exchange futures market. Cocoa beans are the primary ingredient in chocolate confectionery products that provide the world with a tasty treat that has created millions, if not billions of chocoholics all over the planet.
HSYFB ICE HSY BYCBF
In fact, many of the world's best known and most financially successful products were actually copied from earlier competitors, who have mostly been consigned to the dustbin of history.
HERSHEY, Pa., July 10, 2018 (GLOBE NEWSWIRE) -- The Hershey Company (NYSE:HSY) announced today that it will release its second-quarter sales and earnings results on Thursday, July 26, 2018, and hold a conference call with analysts at 8:30 a.m. ET on that date. The company will webcast live its second-quarter conference call via the Hershey corporate website. Please click here and navigate to “CALENDAR OF EVENTS” for webcast details.
The futures were again trading higher Monday morning. Despite concerns over the recently imposed tariffs around the world, investors and Wall Street have their attention focused on second-quarter earnings results, which will begin this week. The trend of buying the dips has not worked as well as it has in prior years, and many investors have been considering how they want their investments positioned for the longer term.
COF.PRG COF.PRH COF.WS MS.PRE COF.PRP MS.PRF MS.PRG MS.PRA DLPH COF-D COF-C COF-F FEYE MS COF.PRC BIDU COF.PRD HSY COF.PRF HSYFB COF-P COF MS.PRI BJ MS.PRK DNKN TRI
The Hershey Company shares have been out of favor due to higher cocoa prices, tepid top line growth, and higher SG&A spending.
WFC WFCNP WFC.WS HSYFB WFC.PRL WFC.PRJ WFC.PRT WFC.PRR WFC.PRQ WFC.PRP WFC.PRO WFC.PRN WFC.PRY WFC.PRX WFC.PRW HSY WFC.PRV
The world's top food companies and farmers of crops such as beet sugar are pitted against each other as they lobby the U.S. government over plans to label genetically-engineered ingredients.
DANOY BN HSYFB UL UN UNLYF ULVR GPDNF UNLNF HSY
NEW YORK (Reuters) - The world’s top food companies and farmers of crops such as beet sugar are pitted against each other as they lobby the U.S. government over plans to label genetically-engineered ingredients.
DANOY BN HSYFB UL UN UNLYF ULVR GPDNF UNLNF HSY
HERSHEY, Pa., July 03, 2018 (GLOBE NEWSWIRE) -- The Hershey Company (NYSE:HSY) today announced that Damien Atkins has been named Senior Vice President, General Counsel and Secretary, effective August 13. In his new role, Atkins will lead Hershey’s legal, government relations, and corporate secretary functions. He will report directly to Michele Buck, President and Chief Executive Officer. He also will serve as a member of the company’s Executive Committee, a team of the company’s most senior leaders.
PCRFY HSYFB TWX TWC HSY
The Simply Good Foods Company (SMPL - Free Report) was a big mover last session, as the company saw its shares rise more than 5% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company as the stock is now up 15.3% in the past one-month time frame.
GOOS HSYFB ABX SMPL AXTA HSY ABX
Marijuana definitely looks set to boom. California has already legalized recreational pot use, while Canada and New Jersey appear to be poised to allow it. And President Trump recently decided not to interfere with states’ decisions on marijuana legalization. It seems like a great time to buy pot stocks.
PCG HSYFB KHC MDLZ TWNK HSY SMG
Chicago, IL – June 29, 2018 - Stocks in this week’s article The Hershey Company (HSY - Free Report) , Polaris Industries Inc. (PII - Free Report) , Lithia Motors Inc. (LAD - Free Report) , Fluidigm Corporation (FLDM - Free Report) and Univar Inc. (UNVR - Free Report) .
RYAM UNVR HSYFB WLL RL FLDM WCG RYAM.PRA PII LAD GIII HSY
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
as of ET